Related Experiment Video

Updated: May 10, 2026

Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing
08:19

Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing

Published on: July 7, 2020

Lipid a biosynthesis of multidrug-resistant pathogens - a novel drug target

Chang-Ro Lee1, Jung Hun Lee, Byeong Chul Jeong

  • 1National Leading Research Laboratory, Department of Biological Sciences, Myongji University, 116 Myongjiro, Yongin, Gyeonggido 449-728, Republic of Korea. sangheelee@mju.ac.kr.

Current Pharmaceutical Design
|July 9, 2013
PubMed

Insights

Multidrug-resistant Gram-negative infections require new treatments. Targeting lipid A biosynthesis enzymes (LpxA, LpxC, LpxD) offers a promising strategy for novel antibiotic development against these challenging pathogens.

Area of Science:

  • Microbiology
  • Drug Discovery
  • Biochemistry

Background:

  • Multidrug-resistant (MDR) Gram-negative pathogens present a significant global health challenge.
  • Lipid A biosynthesis is essential for Gram-negative bacteria, making it a viable target for new antibiotics.
  • The enzymes UDP-N-acetylglucosamine acyltransferase (LpxA), UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase (LpxC), and UDP-3-O-(R-3-hydroxyacyl)glucosamine N-acyltransferase (LpxD) are key in this pathway.

Purpose of the Study:

  • To review recent advancements in the structural biology of LpxA, LpxC, and LpxD.
  • To discuss structure-based drug design strategies targeting these essential enzymes.
  • To highlight their potential as targets for novel Gram-negative antibacterial agents.

Main Methods:

  • Literature review of structural studies on LpxA, LpxC, and LpxD.
  • Analysis of structure-based drug design approaches.
  • Synthesis of current research on targeting lipid A biosynthesis.

Main Results:

  • Detailed structural insights into LpxA, LpxC, and LpxD have been elucidated.
  • Structure-activity relationships for potential inhibitors are being explored.
  • Several structure-based drug design strategies show promise for developing new antibiotics.

Conclusions:

  • The LpxA, LpxC, and LpxD enzymes represent attractive targets for combating MDR Gram-negative bacterial infections.
  • Continued structural and medicinal chemistry efforts are crucial for realizing their therapeutic potential.
  • Targeting lipid A biosynthesis is a key strategy for future antibiotic development.

More Related Videos

Isolation of Lipoprotein Particles from Chicken Egg Yolk for the Study of Bacterial Pathogen Fatty Acid Incorporation into Membrane Phospholipids11:59

Isolation of Lipoprotein Particles from Chicken Egg Yolk for the Study of Bacterial Pathogen Fatty Acid Incorporation into Membrane Phospholipids

Published on: May 15, 2019

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...